BioSpace News Archive

Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series on November 7, 2023.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Parhelia Biosciences, the leader in sample preparation for tissue staining and spatial analysis, is pleased to announce the successful completion of its Series A financing round.

ORIC Pharmaceuticals, Inc. announced that the company will present two poster presentations at the European Society of Medical Oncology Congress 2023 taking place October 20-24, 2023, in Madrid, Spain.

Stoke Therapeutics, Inc. announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common stock to 1 new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH® (tenapanor).

Ardelyx, Inc. announced that it has amended the debt financing agreement with investment affiliates managed by SLR Capital Partners it originally entered into in February 2022.

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Ascentage Pharma announced that the registrational Phase III study of olverembatinib, Ascentage Pharma’s lead drug candidate, combined with chemotherapy, versus imatinib combined with chemotherapy in treatment-naïve patients with Philadelphia chromosome-positive acute lymphoblastic leukemia has dosed its first patient.

RadNet, Inc. announced that it will host a conference call to discuss its third quarter 2023 financial results on Thursday, November 9th, 2023 at 7:30 a.m. Pacific Time.